Download Files:
Products Details
Product Description
– NU5455 is a potent, selective, and orally active inhibitor of DNA-PKcs. NU5455 administration increases both the efficacy and the toxicity of a parenterally administered topoisomerase inhibitor. NU5455 enhances the activity of Doxorubicin released locally in liver tumor xenografts without inducing any adverse effect[1].
Web ID
– HY-145427
Shipping
– Room temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C34H33N3O5S
References
– [1]Willoughby CE, et al. Selective DNA-PKcs inhibition extends the therapeutic index of localized radiotherapy and chemotherapy. J Clin Invest. 2020;130(1):258-271.
CAS Number
– 1257235-99-6
Molecular Weight
– 595.71
SMILES
– CN(C1=CC=C2SC3=C(C4=C(OC(N5CC(CC6)OC6C5)=CC7=O)C7=CC=C4)C=CC=C3C2=C1)C(CN8CCOCC8)=O
Clinical Information
– No Development Reported
Research Area
– Cancer
Solubility
– 10 mM in DMSO
Target
– DNA-PK
Pathway
– Cell Cycle/DNA Damage;PI3K/Akt/mTOR
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
